Typically, two drugs are used,
of which one is often platinum-based either cisplatin or Carboplatin.
For patients in whom cisplatin cannot be used, Carboplatin can be substituted
but non-randomised data have shown lower response rates and high rates of haematological toxicity for Carboplatin-based combinations, albeit with similar survival figures to patients receiving cisplatin.